Derma Sciences achieves closure as diabetic foot ulcer drug meets Phase II goal
This article was originally published in Scrip
Executive Summary
Derma Sciences has reported positive results from a Phase II trial with its investigational diabetic foot wound drug, the topical angiotensin analog DSC127, saying that those treated with a high dose of the compound exceeded the primary endpoint of improving complete healing of wounds within the 12-week duration by at least 15 percentage points, against a placebo. The company now plans to meet with the US FDA to advance the product into Phase III trials.